Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $9.13 Analyst target: $36.27 Upside: 297.26%
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. The company is headquartered in Boston, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.